Todt H, Zojer N, Raberger G, Schütz W
Pharmakologisches Institut, Universität Wien, Vienna, Austria.
Eur J Pharmacol. 1994 Nov 14;265(1-2):43-52. doi: 10.1016/0014-2999(94)90221-6.
Prolongation of action potential duration during treatment with agents that possess class I antiarrhythmic activity may result in a clinically relevant increase in Na+ channel block. In order to test this hypothesis in vivo, the effect of QT prolongation on intraventricular conduction was assessed during administration of mexiletine. Epicardial His bundle recordings were made in anesthetized guinea pigs. After abolition of spontaneous sinus node activity by application of high-frequency current to the sinus node area, the hearts were paced via the left atrium. Administration of the class III antiarrhythmic agent dofetilide (10 micrograms/kg i.v.; n = 6) significantly prolonged QT intervals without a significant effect on HV intervals. Infusion of mexiletine (bolus 2 mg/kg + 0.18 mg/kg per min i.v.; n = 6) produced significant increases in HV intervals at cycle lengths of 200 and 300 ms. Subsequent addition of dofetilide (20 micrograms/kg i.v.) to mexiletine induced similar increases in QT intervals as single treatment with 10 micrograms/kg dofetilide and significantly enhanced the rate-dependent conduction slowing. Upon abruptly decreasing the pacing cycle length from 500 ms to 300 ms, conduction slowing developed with a rate constant of 1.0 +/- 0.2 beat-1 after mexiletine and with a rate constant of 1.1 +/- 0.2 beat-1 after subsequent addition of dofetilide (P = n.s.). After rapid stimulation at a cycle length of 250 ms the conduction slowing produced by mexiletine recovered with a time constant of 174 +/- 24 ms. No further change of this recovery time constant was observed after subsequent addition of dofetilide to mexiletine (160 +/- 19 ms, P = n.s.). Thus action potential duration, as reflected by the QT interval, is an important modulator of the magnitude Na+ channel block in vivo. The kinetic parameters of Na+ channel block produced by mexiletine, however, remain unchanged by prolongation of action potential duration after addition of dofetilide.
使用具有Ⅰ类抗心律失常活性的药物治疗期间,动作电位时程的延长可能导致钠通道阻滞在临床上出现显著增加。为了在体内验证这一假设,在美西律给药期间评估QT间期延长对心室内传导的影响。在麻醉的豚鼠身上进行心外膜希氏束记录。通过向窦房结区域施加高频电流消除自发窦房结活动后,经左心房对心脏进行起搏。静脉注射Ⅲ类抗心律失常药物多非利特(10微克/千克;n = 6)可显著延长QT间期,而对HV间期无显著影响。静脉输注美西律(推注2毫克/千克 + 0.18毫克/千克每分钟;n = 6)在周期长度为200和300毫秒时使HV间期显著增加。随后在美西律中加入多非利特(静脉注射20微克/千克),QT间期的增加与单次使用10微克/千克多非利特相似,并显著增强了频率依赖性传导减慢。当起搏周期长度从500毫秒突然降至300毫秒时,美西律给药后传导减慢以1.0±0.2次/搏的速率常数发展,加入多非利特后以1.1±0.2次/搏的速率常数发展(P = 无显著性差异)。在周期长度为250毫秒的快速刺激后,美西律产生的传导减慢以174±24毫秒的时间常数恢复。在美西律中加入多非利特后,未观察到该恢复时间常数的进一步变化(160±19毫秒,P = 无显著性差异)。因此,QT间期所反映的动作电位时程是体内钠通道阻滞程度的重要调节因子。然而,加入多非利特使动作电位时程延长后,美西律产生的钠通道阻滞的动力学参数保持不变。